Iran Achieves Technology to Produce Slow-Release Medicine

“In situ forming systems is the newest and most advanced method of drug production, and we have patented the drug triptorlin acetate (a drug for treating endometriosis, reducing the size of uterine fibroids, and treating prostate cancer) with in situ technology as the only producer of this drug with this type of technology in the world,” said Mohammad Taqi Fathi, the managing director of the knowledge-based company.

“Also, we are the only manufacturer of variomitexan drug in Iran and we have two important and strategic drugs variopeptil and lopromer in the production portfolio of our company which are used in the treatment of prostate diseases, breast cancer, uterine diseases and premature puberty,” he added.

“Lopromer (gonadotropin-releasing hormone agonist) is a specialized oncology drug used for different therapeutic purposes depending on age and gender. It is used in women to treat endometriosis, fibroids and breast cancer, in men to treat prostate cancer, and in children to treat premature central puberty,” Fathi said.

Slow-release medicine refers to medications that release a consistent amount of the drug over a longer period of time.

Slow-release medications may also be referred to as extended-release or controlled-release medicines, and are often labeled with an ER, XR, or CR to designate them as such.

4155/v